NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Analysis Summary
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a market cap of $3.49B with year-over-year revenue growth of -50.6%. Net margin stands at -905.7%. The stock trades at a P/E ratio of -16.4.
Key Takeaways
- Revenue changed -50.6% year-over-year
- Net margin of -905.7%
- P/E ratio of -16.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, NAMS posted revenue growth of -50.6% and trades at a P/E of -16.4.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.